Community Feature


AlphaMed Press partners with Oxford University Press to publish journals

July 6, 2021 - Oxford University Press (OUP) and AlphaMed Press are pleased to announce that OUP will publish three AlphaMed Press journals: The Oncologist, STEM CELLS, and STEM CELLS Translational Medicine beginning January 2022.


 

Visit our online booth to learn more about the latest journal initiatives.


 

Racism and Cancer Care

This series examines how racism affects the prevention, treatment, and delivery of care to minority communities, and to what extent we have adequately incorporated a culture of equity in all phases of our work and our personal lives. To this end, The Oncologist has invited the submission of papers on a broad spectrum of topics, from disparities in outcomes, to the recruitment and training of minority cancer physicians and scientists, to the personal experiences of minority professionals as they practice cancer medicine and pursue careers in the academic community.

Read the Collection.


 

The Oncologist family is saddened by the death of oncology pioneer and Pinedo Cancer Care Prize winner José Baselga. You can read Dr. Bruce A. Chabner's "Remembering José" in our journal


 

Congratulations to Alessio Cortellini, MD

Dr. Cortellini’s work in risks of immunotherapy treatment for patients with pre‐existing autoimmune disease earns him The Oncologist’sYoung Investigator Award. Read more about Dr. Cortellini and his research.

 

 

 

 


 

Biomarkers in Breast Carcinoma

Richard S.P. Huang, et al., The Oncologist

This article reports the current landscape of biomarkers in breast cancer, focusing on patients using comprehensive genomic profiling and PD‐L1 immunohistochemistry in addition to the previous standard of care diagnostics for hormone receptor and human epidermal receptor 2 identification. The relationship between different immunotherapy biomarkers in patients with triple‐negative breast cancer is examined.
 

 

 


 

Real-World PFS for ALK TKIs in ALK+ NSCLC Patients

Mohammad Jahanzeb, et al., The Oncologist

Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.

 


 

Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis

Saptaparni Ghosh, et al., The Oncologist

Currently, there are no guidelines for chemotherapy administration in hepatitis C virus-positive patients with breast cancer. This article addresses the knowledge gap, comparing breast cancer patients with and without concurrent hepatitis C virus to determine level of tolerance to treatment.
 

 

 


 

ALK -Rearranged Non‐Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling

Malinda Itchins, et al., The Oncologist

This report underscores the importance of genetic analysis of serial biopsies to capture the dynamic therapeutic vulnerabilities within a patient’s tumor, while providing a perspective on the complexity of ALK tyrosine kinase inhibitor treatment sequencing.
 

 

 


 

Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Mojun Zhu, et al., The Oncologist

This article describes a patient with high-grade pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to Lutetium-177-Dotatate and summarizes the current state of clinical management of high-grade neuroendocrine tumors.